Having trouble accessing articles? Reset your cache.

Afatinib: Phase IIb/III data

The double-blind, international Phase IIb/III LUX-Lung 1 trial in >580 patients with advanced NSCLC who had previously received chemotherapy and either Tarceva erlotinib or Iressa gefitinib showed that afatinib

Read the full 294 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE